Mouse models in squamous cell lung cancer: impact for drug discovery

References

• Stewart BW, Wild CP. World cancer report 2014. Lyon: International Agency for Research on Cancer; 2014. 630p.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Derman BA, Mileham KF, Bonomi PD, et al. Treatment of advanced squamous cell carcinoma of the lung: a review. Transl Lung Cancer Res. 2015;4(5):524–532.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260.
   PubMed Web of Science ®Google Scholar
• Miller YE. Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol. 2005;33(3):216–223.
   PubMed Web of Science ®Google Scholar
• Funai K, Yokose T, Ishii G, et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol. 2003;27(7):978–984.
   PubMed Web of Science ®Google Scholar
• Cheng H-Y, Ko F-H, Lai L-J. Using novel method to detect different cancer-cell stages of model human lung carcinoma. J Clin Lab Anal. 2015;29(4):285–288.
   PubMed Web of Science ®Google Scholar
• Shum E, Wang F, Kim S, et al. Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials. Expert Opin Investig Drugs. 2017;26(4):415–426.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–525.
   PubMed Web of Science ®Google Scholar
• Wang Y, Rouggly L, You M, et al. Animal models of lung cancer characterization and use for chemoprevention research. Prog Mol Biol Transl Sci. 2012;105:211–226.
   PubMed Web of Science ®Google Scholar
• You MS, Rouggly LC, You M, et al. Mouse models of lung squamous cell carcinomas. Cancer Metastasis Rev. 2013;32(1–2):77–82.
   PubMed Web of Science ®Google Scholar
• Lovly C, Horn L, Pao W. Molecular profiling of lung cancer. My Cancer Genome. 2016 [cited 2016 Mar 28]. Available from: https://www.mycancergenome.org/content/disease/lung-cancer/
   Google Scholar
• Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000;60(7):1949–1960.
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou V, Redman M, Gandara DR, et al. Lung-MAP (S1400) lung cancer master protocol: accrual, demographics, and molecular markers. J Clin Oncol. 2016;34(suppl):abstr 9088.
   Google Scholar
• Aggarwal C, Redman MW, Lara P, et al. Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D. J Clin Oncol. 2017;35(suppl):abstr 9055.
   Google Scholar
• Wade JL, Langer CJ, Redman M, et al. A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B. J Clin Oncol. 2017;35(suppl):abstr 9054.
   Google Scholar
• Edelman MJ, Redman MW, Albain KS, et al. A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): lung-MAP sub-study SWOG S1400C. J Clin Oncol. 2017;35(suppl):abstr 9056.
   Google Scholar
• Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother Pharmacol. 1998;41(6):497–504.
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Singh RK, Fidler IJ, et al. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol. 2007;170(3):793–804.
   PubMed Web of Science ®Google Scholar
• Kellar A, Egan C, Morris D. Preclinical murine models for lung cancer: clinical trial applications. Biomed Res Int. 2015;2015:1–17.
   Google Scholar
• Kwon M-C, Berns A. Mouse models for lung cancer. Mol Oncol. 2013;7(2):165–177.
   PubMed Web of Science ®Google Scholar
• Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev. 2005;19(6):643–664.
   PubMed Web of Science ®Google Scholar
• Farago AF, Snyder EL, Jacks T. SnapShot: lung cancer models. Cell. 2012;149(1):246–e1.
   PubMed Web of Science ®Google Scholar
• Ferone G, Song J-Y, Sutherland KD, et al. SOX2 is the determining oncogenic switch in promoting lung squamous cell carcinoma from different cells of origin. Cancer Cell. 2016;30(4):519–532.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Hirsch FR, Minna JD. From mice to men and back: an assessment of preclinical model systems for the study of lung cancers. J Thorac Oncol. 2016;11(3):287–299.
   PubMed Web of Science ®Google Scholar
• Onn A, Isobe T, Itasaka S, et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res. 2003;9(15):5532–5539.
   PubMed Web of Science ®Google Scholar
• Williams SS, Alosco TR, Mayhew E, et al. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res. 1993;53(17):3964–3967.
   PubMed Web of Science ®Google Scholar
• Kasiri S, Shao C, Chen B, et al. GLI1 blockade potentiates the antitumor activity of PI3K antagonists in lung squamous cell carcinoma. Cancer Res. 2017;77(16):4448–4459.
   PubMed Web of Science ®Google Scholar
• Ming F, Sun Q. Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma. Mol Med Rep. 2017;16(1):746–754.
   PubMed Web of Science ®Google Scholar
• Yang J, Gao F, Xu X, et al. Targeting protein for Xenopus kinesin-like protein 2 knockdown enhances radiation sensitivity of human lung squamous carcinoma cell. Clin Exp Pharmacol Physiol. 2017;44(10):1060–1068.
   PubMed Web of Science ®Google Scholar
• Nettesheim P, Hammons AS. Induction of squamous cell carcinoma in the respiratory tract of mice. J Natl Cancer Inst. 1971;47(3):697–701.
   PubMedGoogle Scholar
• Rehm S, Lijinsky W, Singh G, et al. Mouse bronchiolar cell carcinogenesis. Histologic characterization and expression of Clara cell antigen in lesions induced by N-nitrosobis-(2-chloroethyl) ureas. Am J Pathol. 1991;139(2):413–422.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Z, Yan Y, et al. A chemically induced model for squamous cell carcinoma of the lung in mice: histopathology and strain susceptibility. Cancer Res. 2004;64(5):1647–1654.
   PubMed Web of Science ®Google Scholar
• Yamano S, Gi M, Tago Y, et al. Role of deltaNp63(pos)CD44v(pos) cells in the development of N-nitroso-tris-chloroethylurea-induced peripheral-type mouse lung squamous cell carcinomas. Cancer Sci. 2016;107(2):123–132.
   PubMed Web of Science ®Google Scholar
• Xiong D, Pan J, Zhang Q, et al. Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents. Oncotarget. 2017;8(12):18885–18900.
   PubMedGoogle Scholar
• Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007;448(7155):807–810.
   PubMed Web of Science ®Google Scholar
• Goodwin J, Neugent ML, Lee SY, et al. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nat Commun. 2017;8:15503.
   PubMed Web of Science ®Google Scholar
• Liu S, Chen Z, Zhu F, et al. IkappaB kinase alpha and cancer. J Interferon Cytokine Res. 2012;32(4):152–158.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Jiang Q, Willette-Brown J, et al. The pivotal role of IKKalpha in the development of spontaneous lung squamous cell carcinomas. Cancer Cell. 2013;23(4):527–540.
   PubMed Web of Science ®Google Scholar
• Perera SA, Li D, Shimamura T, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A. 2009;106(2):474–479.
   PubMed Web of Science ®Google Scholar
• Malkoski SP, Cleaver TG, Thompson JJ, et al. Role of PTEN in basal cell derived lung carcinogenesis. Mol Carcinog. 2014;53(10):841–846.
   PubMed Web of Science ®Google Scholar
• Xu C, Fillmore CM, Koyama S, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell. 2014;25(5):590–604.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Berrett KC, Kc U, et al. Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer. Cell Rep. 2014;8(1):40–49.
   PubMed Web of Science ®Google Scholar
• Lu Y, Futtner C, Rock JR, et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One. 2010;5(6):e11022.
   PubMed Web of Science ®Google Scholar
• Jeong Y, Hoang NT, Lovejoy A, et al. Role of KEAP1/NRF2 and tp53 mutations in lung squamous cell carcinoma development and radiation resistance. Cancer Discov. 2017;7(1):86–101.
   PubMed Web of Science ®Google Scholar
• Moro M, Bertolini G, Tortoreto M, et al. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J Biomed Biotechnol. 2012;2012:1–11.
   PubMedGoogle Scholar
• Fu S, Zhao J, Bai H, et al. High-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies. Thorac Cancer. 2016;7(1):100–110.
   PubMed Web of Science ®Google Scholar
• Fichtner I, Rolff J, Soong R, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008;14(20):6456–6468.
   PubMed Web of Science ®Google Scholar
• Merk J, Rolff J, Becker M, et al. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg. 2009;36(3):454–459.
   PubMed Web of Science ®Google Scholar
• Wang D, Pham N-A, Tong J, et al. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. Int J Cancer. 2017;140(3):662–673.
   PubMed Web of Science ®Google Scholar
• Ilie M, Nunes M, Blot L, et al. Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps. Cancer Med. 2015;4(2):201–211.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gable T, Ma MZ, et al. A piRNA-like small RNA induces chemoresistance to cisplatin-based therapy by inhibiting apoptosis in lung squamous cell carcinoma. Mol Ther Nucleic Acids. 2017;6:269–278.
   PubMedGoogle Scholar
• Ruggeri BA, Camp F, Miknyoczki S. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol. 2014;87(1):150–161.
   PubMed Web of Science ®Google Scholar
• de Seranno S, Meuwissen R. Progress and applications of mouse models for human lung cancer. Eur Respir J. 2010;35(2):426–443.
   PubMed Web of Science ®Google Scholar
• Yamori T, Sato S, Chikazawa H, et al. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res. 1997;88(12):1205–1210.
   PubMedGoogle Scholar
• Dong X, Guan J, English JC, et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res. 2010;16(5):1442–1451.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li R, Chen X, et al. Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer. Oncotarget. 2017;8(42):72447–72456.
   PubMedGoogle Scholar
• Singh M, Murriel CL, Johnson L. Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res. 2012;72(11):2695–2700.
   PubMed Web of Science ®Google Scholar
• Steele VE, Lubet RA. The use of animal models for cancer chemoprevention drug development. Semin Oncol. 2010;37(4):327–338.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Z, Garbow JR, et al. Chemoprevention of lung squamous cell carcinoma in mice by a mixture of Chinese herbs. Cancer Prev Res (Phila). 2009;2(7):634–640.
   PubMed Web of Science ®Google Scholar
• Wang Y, James M, Wen W, et al. Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. Mol Cancer Ther. 2010;9(11):3074–3082.
   PubMed Web of Science ®Google Scholar
• Khan N, Afaq F, Kweon M-H, et al. Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res. 2007;67(7):3475–3482.
   PubMed Web of Science ®Google Scholar
• Mazzilli SA, Hershberger PA, Reid ME, et al. Vitamin D repletion reduces the progression of premalignant squamous lesions in the NTCU lung squamous cell carcinoma mouse model. Cancer Prev Res (Phila). 2015;8(10):895–904.
   PubMed Web of Science ®Google Scholar
• Azpilikueta A, Agorreta J, Labiano S, et al. Successful immunotherapy against a transplantable mouse squamous lung carcinoma with anti-PD-1 and anti-CD137 monoclonal antibodies. J Thorac Oncol. 2016;11(4):524–536.
   PubMed Web of Science ®Google Scholar
• Wei H, Zhao L, Hellstrom I, et al. Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy. Oncoimmunology. 2014;3:e28248.
   PubMed Web of Science ®Google Scholar